Journal Mobile Options
Table of Contents
Vol. 5, No. 2, 2012
Issue release date: May – August
Add to my selection Citation Download
Open Access Gateway
Case Rep Oncol 2012;5:388–393
(DOI:10.1159/000341260)
Published: July 2012

Primary Burkitt’s Lymphoma Presenting as a Rapidly Growing Thyroid Mass

Yildiz I.a · Sen F.a · Toz B.b · Kilic L.a · Agan M.c · Basaran M.a
aDepartment of Medical Oncology, Institute of Oncology, and Departments of bInternal Medicine and cPathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey Case Rep Oncol 2012;5:388–393 (DOI:10.1159/000341260)

Abstract

A 31-year-old male patient presented with a rapidly growing neck mass with normal thyroid function tests. Ultrasonography showed thyroidal expansion, a hypoechoic nodule that completely filled the right lobe, and 2 hypoechoic lymphadenopathies in the right jugulodigastric chain. The patient underwent right total and left subtotal thyroidectomy, following the diagnosis of nodular goiter; however, postoperative histopathological evaluation demonstrated primary Burkitt’s lymphoma of the thyroid gland. The tumor was staged as stage 1, and R-hyper-CVAD protocol (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone) was administered. The protocol was changed to R-CHOP after 4 cycles due to recurrent grade III/IV cytopenias and febrile neutropenia. The PET-CT scans performed after chemotherapy and at the 6-month follow-up were normal. In summary, we reported a case with a diagnosis of Burkitt’s lymphoma, which is a rare type of primary thyroid lymphoma.

 goto top of outline Author Contacts

Ibrahim Yildiz, MD
Department of Medical Oncology
Institute of Oncology, Istanbul University
TR–21234 Istanbul (Turkey)
Tel. +90 505 746 51 78, E-Mail dr_ibrahim2000@yahoo.com


 goto top of outline Article Information

Published online: July 24, 2012
Number of Print Pages : 6
Number of Figures : 2,


 goto top of outline Publication Details

Case Reports in Oncology

Vol. 5, No. 2, Year 2012 (Cover Date: May - August)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 1662-6575 (Print), eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO


Open Access License / Drug Dosage

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.